Red Flags Detected

  • Delisting (new) — Nasdaq formally notified company of non-compliance with minimum bid price and equity requirements, creating delisting risk if not cured by December 2026.
  • Related Party (new) — The $5M convertible bridge note comes from V-Co 4, an affiliate of existing investor and advisor New Seneca Partners, raising potential conflicts of interest.
NASDAQ: VVOS Vivos Therapeutics, Inc. 8-K

Vivos restructures $4.5M debt, secures $5M bridge loan, receives Nasdaq delisting warning

Filed June 8, 2026 · Period ending June 8, 2026 · ~2 min read

Key Changes

  • high

    Vivos agreed to exchange up to $4.5M of Streeterville debt for preferred stock in two tranches, contingent on raising $4.5M in new equity by June 15, 2026. Remaining debt gets 6-month maturity extension and reduced monthly payments from $550K to $225K.

    Item 1.01: Exchange Agreement verify on EDGAR →
  • high

    Company secured $5M convertible bridge note from related party V-Co 4 (affiliate of existing investor/advisor) with 10% discount, initially funded $500K. Note converts to equity in planned $5.5M financing expected by June 30, 2026.

    Item 1.01: V-Co 4 Note verify on EDGAR →
  • high

    Nasdaq notified Vivos on June 5 of non-compliance with $1.00 minimum bid price requirement. Company has 180 days until December 2, 2026 to regain compliance or face delisting. Also non-compliant with $2.4M minimum equity requirement.

    Item 3.01: Nasdaq Notice verify on EDGAR →

2 more material changes plus the full narrative summary — create a free account to see the rest. Takes 30 seconds.

Partner

Trade VVOS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 8, 2026 3:35 PM